Beacon Biosignals

Boston, MA · Founded 2019 · Privately Held (backing)

Developer of an artificial intelligence-based neurotechnology platform designed for accelerating the clinical development of therapeutics targeting brain health. Beacon Biosignals is based in Boston, MA and was founded in 2019. It was valued at $334 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $127 million across 2 recorded rounds; the latest was a $103 million later-stage round in Oct 2025.

PMV mark · valuation
$334.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$126.9M
Last round
Later Stage VC
Oct 2025

Who backs Beacon Biosignals?

20 investors
InvestorType
Alumni VenturesVenture capital
General CatalystVenture capital
GVVenture capital
Samsung NEXT VenturesVenture capital
Inovia CapitalVenture capital
Catalio Capital ManagementVenture capital
S32Venture capital
Casdin CapitalVenture capital
Logos CapitalHedge fund
Nexus NeuroTech VenturesVenture capital
+ 10 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Beacon Biosignals investors

20 investors are on record for Beacon Biosignals, including Alumni Ventures, General Catalyst, GV and Samsung NEXT Ventures. By type, the record holds 9 venture capital firms and 1 hedge fund. The later-stage round in Oct 2025 drew 43 investors.

Free account
More of Beacon Biosignals with a free account
  • ·The complete investor list: 20 names
  • ·Watch Beacon Biosignals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 20 firms already write checks for companies like Beacon Biosignals. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View